Eikon Therapeutics, Inc. (EIKN)
7.26
-0.98
(-11.89%)
USD |
NASDAQ |
Oct 23, 16:00
7.24
-0.02
(-0.28%)
After-Hours: 20:00
Eikon Therapeutics Enterprise Value : 113.76M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 113.76M |
| October 22, 2026 | 166.83M |
| October 21, 2026 | 153.83M |
| October 20, 2026 | 163.58M |
| October 19, 2026 | 137.59M |
| October 16, 2026 | 122.43M |
| October 15, 2026 | 128.92M |
| October 14, 2026 | 100.22M |
| October 13, 2026 | 84.52M |
| October 12, 2026 | 113.76M |
| October 09, 2026 | 125.13M |
| October 08, 2026 | 126.76M |
| October 07, 2026 | 128.92M |
| October 06, 2026 | 127.30M |
| October 05, 2026 | 128.92M |
| October 02, 2026 | 117.55M |
| October 01, 2026 | 121.88M |
| September 30, 2026 | 156.00M |
| September 29, 2026 | 148.96M |
| September 28, 2026 | 148.96M |
| September 25, 2026 | 149.50M |
| September 24, 2026 | 169.54M |
| September 23, 2026 | 160.87M |
| September 22, 2026 | 206.90M |
| September 21, 2026 | 198.78M |
| Date | Value |
|---|---|
| September 18, 2026 | 205.27M |
| September 17, 2026 | 186.32M |
| September 16, 2026 | 181.45M |
| September 15, 2026 | 234.51M |
| September 14, 2026 | 227.47M |
| September 11, 2026 | 204.73M |
| September 10, 2026 | 219.35M |
| September 09, 2026 | 301.66M |
| September 08, 2026 | 300.58M |
| September 04, 2026 | 308.70M |
| September 03, 2026 | 314.11M |
| September 02, 2026 | 336.86M |
| September 01, 2026 | 309.78M |
| August 31, 2026 | 287.04M |
| August 28, 2026 | 315.20M |
| August 27, 2026 | 344.44M |
| August 26, 2026 | 369.34M |
| August 25, 2026 | 400.21M |
| August 24, 2026 | 324.94M |
| August 21, 2026 | 337.40M |
| August 20, 2026 | 302.74M |
| August 19, 2026 | 370.97M |
| August 18, 2026 | 351.48M |
| August 17, 2026 | 287.58M |
| August 14, 2026 | 318.99M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -88.41M |
| Total Expenses (Quarterly) | 88.41M |
| EPS Diluted (Quarterly) | -1.633 |
| Earnings Yield | -90.63% |
| Normalized Earnings Yield | -90.63 |